Davis's Drug Guide
abciximab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
**Off Market Drug**
This medication is no longer available in the United States. Information provided here is for reference purposes only.
Pronunciation:
ab-six-i-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- ReoPro
Ther. Class.
Pharm. Class.
glycoprotein iib iiia inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Abciximab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/51002/all/abciximab.
Vallerand AHA, Sanoski CAC, Quiring CC. Abciximab. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51002/all/abciximab. Accessed May 31, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Abciximab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51002/all/abciximab
Vallerand AHA, Sanoski CAC, Quiring CC. Abciximab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 May 31]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51002/all/abciximab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - abciximab
ID - 51002
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51002/all/abciximab
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -